Lipocalin 2 (LCN2)
Lipocalin 2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is a secreted lipocalin-family protein with important roles in inflammation, tissue injury responses, and metabolic regulation.
Lipocalin 2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is a secreted lipocalin-family protein with important roles in inflammation, tissue injury responses, and metabolic regulation. It is widely studied as a biomarker of kidney injury, but it is also increasingly recognized as a biologically active mediator rather than only a passive marker. In disease settings, LCN2 is often induced by inflammatory stimuli and stress signals, including bacterial lipopolysaccharide, high glucose, and other injury-associated cues.
Beyond its established use in renal research, LCN2 has been implicated in metabolic dysfunction associated steatotic liver disease, Metabolic dysfunction associated steatohepatitis (MASH), muscle atrophy, and neuroinflammatory responses. Recent studies also connect LCN2 with pathways involving IL-6, iNOS, PPARα activation, oxidative stress, and renal tubular injury markers such as KIM-1. These findings support a broader view of LCN2 as a stress-responsive mediator linking inflammation, organ injury, and systemic metabolic disease.
Where the papers sit
11 papers from the last 6 months study Lipocalin 2 (LCN2) directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 observational · 1 human data · 5 preclinical · 3 unclassified
Themes one subject · 1 paradigm shift · 1 new direction
Those 11 are all about one subject.
-
LCN2-Related Disease Research
LCN2 is being examined across inflammatory injury, kidney dysfunction, muscle atrophy and gastrointestinal disease. Recurring work links it to NLRP3-mediated pyroptosis, extracellular-matrix remodeling and barrier disruption. Other studies assess LCN2 and related biomarkers for early diagnosis or disease progression. The literature remains broad, with therapeutic inhibition and biomarker validation developing alongside largely separate disease-specific investigations.
LCN2 is a causal driver of muscle wasting across distinct systemic diseases, not merely an associated injury marker
The dexamethasone-induced glucocorticoid-atrophy models and primary myotubes in the study of glucocorticoid-induced muscle atrophy, and the MCD- and GAN-diet MASH models, sarcopenic patients with advanced chronic liver disease, and human myotubes in the study of MASH-associated sarcopenia, independently identify LCN2 as an active mediator of muscle loss rather than simply a disease-associated readout. In the glucocorticoid model, GR directly activates LCN2, whose excess disrupts the extracellular matrix through MMP9, while LCN2 silencing alleviates atrophy; in MASH, liver-secreted LCN2 contributes to liver-to-muscle signaling that induces myotube atrophy and alters mitochondrial metabolism. Together, these findings replace a biomarker-centered account with a cross-disease endocrine and tissue-remodeling mechanism in which LCN2 itself becomes a therapeutic target for muscle wasting 42610529Aug 42270040Jun.
LCN2 is identified as a mediator of NLRP3-dependent neuronal pyroptosis after subarachnoid hemorrhage
Subarachnoid hemorrhage with early brain injury in mice, hemin-treated HT22 neuronal cells, and patient cerebrospinal-fluid samples was used to show that LCN2 is not only associated with neuroinflammation but also promotes neuronal pyroptosis through the NLRP3 inflammasome. LCN2 knockdown reduced pyroptotic injury and neurological damage, while recombinant LCN2 enhanced the pathway, adding an LCN2–NLRP3 mechanism and a potential intervention point to the roles represented elsewhere in the set. 43014014Nov
Papers
The 11 papers from the last 6 months that study Lipocalin 2 (LCN2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
LCN2-Related Disease Research (11)
- Lipocalin-2 mediates pyroptosis in early brain injury after subarachnoid hemorrhage via NLRP3 inflammasome. International immunopharmacology · 11 Nov 2026 PMID 43014014
- Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood-labyrinth barrier disruption in a mouse model of chronic kidney disease. Journal of molecular histology · 30 Aug 2026 PMID 42669095
- Loss of LCN2 Function Ameliorates Glucocorticoid-Induced Muscle Atrophy via Remodeling the Extracellular Matrix. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 18 Aug 2026 PMID 42610529
- Renal and endothelial biomarkers in Chagas disease in the Brazilian Amazon region: Early indicators of kidney injury and disease progression. PloS one · 17 Jul 2026 PMID 42467670
- Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease. BMC gastroenterology · 17 Jul 2026 PMID 42464159
- Multiplexed plasmon-enhanced lateral flow assay for early diagnosis of acute kidney injury. Biosensors & bioelectronics · 8 Jul 2026 PMID 42419079
- A four-gene signature for diagnosis of acute kidney injury following kidney transplantation. Renal failure · 18 Jun 2026 PMID 42315974
- Enhancing the efficacy of ulcerative colitis treatment by inhibiting LCN2-mediated pyroptosis through traditional processing techniques: With the rhizome of Atractylodes macrocephala Koidz. as an example. Journal of ethnopharmacology · 16 Jun 2026 PMID 42302942
- CDK5-p25 Peptide Inhibitor Samples an Intrinsically Disordered Ensemble in Solution. The journal of physical chemistry. B · 12 Jun 2026 PMID 42284526
- Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH. Molecular metabolism · 10 Jun 2026 PMID 42270040
- An optimised lipid nanoparticle platform enables efficient CRISPR/Cas9 genome editing in hard-to-transfect cells. Acta biomaterialia · 29 May 2026 PMID 42214710
By study type
Observational studies and case reports (2)
- Renal and endothelial biomarkers in Chagas disease in the Brazilian Amazon region: Early indicators of kidney injury and disease progression. PloS one · 17 Jul 2026 PMID 42467670
- Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease. BMC gastroenterology · 17 Jul 2026 PMID 42464159
Human data, design not indexed (1)
- Multiplexed plasmon-enhanced lateral flow assay for early diagnosis of acute kidney injury. Biosensors & bioelectronics · 8 Jul 2026 PMID 42419079
Preclinical: animal, cell and lab studies (5)
- Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood-labyrinth barrier disruption in a mouse model of chronic kidney disease. Journal of molecular histology · 30 Aug 2026 PMID 42669095
- A four-gene signature for diagnosis of acute kidney injury following kidney transplantation. Renal failure · 18 Jun 2026 PMID 42315974
- Enhancing the efficacy of ulcerative colitis treatment by inhibiting LCN2-mediated pyroptosis through traditional processing techniques: With the rhizome of Atractylodes macrocephala Koidz. as an example. Journal of ethnopharmacology · 16 Jun 2026 PMID 42302942
- CDK5-p25 Peptide Inhibitor Samples an Intrinsically Disordered Ensemble in Solution. The journal of physical chemistry. B · 12 Jun 2026 PMID 42284526
- An optimised lipid nanoparticle platform enables efficient CRISPR/Cas9 genome editing in hard-to-transfect cells. Acta biomaterialia · 29 May 2026 PMID 42214710
Unclassified: not yet indexed with MeSH (3)
- Lipocalin-2 mediates pyroptosis in early brain injury after subarachnoid hemorrhage via NLRP3 inflammasome. International immunopharmacology · 11 Nov 2026 PMID 43014014
- Loss of LCN2 Function Ameliorates Glucocorticoid-Induced Muscle Atrophy via Remodeling the Extracellular Matrix. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 18 Aug 2026 PMID 42610529
- Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH. Molecular metabolism · 10 Jun 2026 PMID 42270040
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-09-01 by GPT. Drafted by language models from published abstracts; not medical advice.